BackSpyGlass Pharma Common Stock Overview

SpyGlass Pharma Common Stock Long Term Debt

Latest long-term debt for SGP: $1.6M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$1.61M

Peer average

Loading

SpyGlass Pharma Common Stock Long Term Debt History

Loading

SpyGlass Pharma Common Stock vs. peers: Long Term Debt Comparison

Loading

SpyGlass Pharma Common Stock Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

SpyGlass Pharma Common Stock (SGP) FAQ

The latest long-term debt for SGP is $1.6M as of March 2026. Investors often review this figure alongside SpyGlass Pharma Common Stock's historical trend and sector peers before judging valuation or financial health.

A long-term debt figure of $1.6M for SGP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SGP's long-term debt ($1.6M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack SpyGlass Pharma Common Stock's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.